Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwCLL 2019 | Overcoming resistance to BTK inhibition in CLL

Jennifer Woyach • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Selinexor Vecabrutinib Venetoclax

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, elaborates on overcoming resistance to BTK inhibition in chronic lymphocytic leukemia (CLL) patients, touching on the genetic basis to resistance and promising drugs and targets. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Jennifer Woyach

BRUIN CLL-314 study: pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL/SLL
6:46
BRUIN CLL-314 study: pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL/SLL
Jennifer Woyach • 6 Dec 2025
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
2:08
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
Jennifer Woyach • 8 Dec 2025
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
2:54
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach • 8 Dec 2025
Non-immunological approaches being explored for the treatment of CLL
0:51
Non-immunological approaches being explored for the treatment of CLL
Jennifer Woyach • 13 Sep 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Jennifer Woyach • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Jennifer Woyach • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Jennifer Woyach • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Jennifer Woyach • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals